almagate has been researched along with Eye Infections in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cohen, SY; Coscas, G; Creuzot-Garcher, C; Devin, F; Gaudric, A; Korobelnik, JF; Mauget-Faysse, M; Sahel, JA; Soubrane, G; Souied, E; Tadayoni, R; Weber, M | 1 |
| Bakri, SJ; Diago, T; Edwards, AO; McCannel, CA; Pach, JM; Pulido, JS | 1 |
| Cooney, M; Freund, KB; Klancnik, J; Kotsolis, A; Pilli, S; Slakter, J; Sorenson, J; Spaide, RF | 1 |
3 other study(ies) available for almagate and Eye Infections
| Article | Year |
|---|---|
[Evolving intravitreous injection technique].
Topics: Adrenal Cortex Hormones; Antibiotic Prophylaxis; Aptamers, Nucleotide; Comorbidity; Contraindications; Drug Hypersensitivity; Eye Infections; Humans; Informed Consent; Injections; Macular Degeneration; Monitoring, Physiologic; Mydriatics; Practice Guidelines as Topic; Pupil; Retinal Artery Occlusion; Tonometry, Ocular; Unnecessary Procedures; Vitreous Body; Vitreous Hemorrhage | 2008 |
Infectious endophthalmitis after intravitreal injection of antiangiogenic agents.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Ceftazidime; Drug Therapy, Combination; Endophthalmitis; Eye Infections; Female; Humans; Injections; Male; Ranibizumab; Retrospective Studies; Risk Factors; Staphylococcal Infections; Vancomycin; Vitreous Body | 2009 |
Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Endophthalmitis; Eye Infections; Humans; Incidence; Injections; Male; Ranibizumab; Retrospective Studies; Risk Factors; Vascular Endothelial Growth Factor A; Visual Acuity; Vitreous Body | 2008 |